Gene-Edited immune cells take aim at stubborn leukemia
NCT ID NCT06345027
Summary
This early-phase study is testing a new type of cell therapy for patients whose leukemia has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer cells carrying a specific protein called CD70, and then infuse them back into the patient. The main goals are to find a safe dose, understand side effects, and see if this approach shows any promise against these difficult-to-treat blood cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Methodist Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.